A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases.
Aged
Chemoradiotherapy
/ adverse effects
Cisplatin
/ administration & dosage
Diffusion Magnetic Resonance Imaging
Embolization, Therapeutic
/ adverse effects
Female
Follow-Up Studies
Humans
Liver
/ blood supply
Liver Neoplasms
/ mortality
Male
Melanoma
/ mortality
Middle Aged
Pilot Projects
Progression-Free Survival
Uveal Neoplasms
/ mortality
Yttrium Radioisotopes
/ administration & dosage
anti‐PD‐1 therapy
chemotherapy
uveal melanoma
yttrium‐90 microspheres
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
24
01
2019
revised:
22
03
2019
accepted:
03
04
2019
entrez:
29
7
2020
pubmed:
29
7
2020
medline:
5
10
2021
Statut:
ppublish
Résumé
Metastatic uveal melanoma is a highly aggressive disease with no standard of care treatment option. A large proportion of patients have liver-only metastatic disease which raises the question if liver-directed therapy can be efficacious in this subpopulation. The study aims to evaluate the safety and efficacy of radiosensitizing chemotherapy in combination with yttrium-90 microspheres in patients with uveal melanoma with liver-only metastases. This single arm, open labeled, non-randomized study enrolled 10 patients with liver-only metastatic uveal melanoma between November 2012 and January 2018. Eligible patients received intrahepatic yttrium-90 microspheres followed by intravenous cisplatin (20 mg/m The combination of cisplatin with yttrium-90 microspheres was well tolerated; however, it was associated with intrahepatic disease control of relatively short duration. No responses were seen in patients treated with immune checkpoint inhibitors post radioembolization.
Sections du résumé
BACKGROUND
Metastatic uveal melanoma is a highly aggressive disease with no standard of care treatment option. A large proportion of patients have liver-only metastatic disease which raises the question if liver-directed therapy can be efficacious in this subpopulation.
AIMS
The study aims to evaluate the safety and efficacy of radiosensitizing chemotherapy in combination with yttrium-90 microspheres in patients with uveal melanoma with liver-only metastases.
METHODS AND RESULTS
This single arm, open labeled, non-randomized study enrolled 10 patients with liver-only metastatic uveal melanoma between November 2012 and January 2018. Eligible patients received intrahepatic yttrium-90 microspheres followed by intravenous cisplatin (20 mg/m
CONCLUSION
The combination of cisplatin with yttrium-90 microspheres was well tolerated; however, it was associated with intrahepatic disease control of relatively short duration. No responses were seen in patients treated with immune checkpoint inhibitors post radioembolization.
Identifiants
pubmed: 32721131
doi: 10.1002/cnr2.1183
pmc: PMC7941455
doi:
Substances chimiques
Yttrium Radioisotopes
0
Yttrium-90
1K8M7UR6O1
Cisplatin
Q20Q21Q62J
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1183Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
J Vasc Interv Radiol. 2015 Apr;26(4):523-32.e2
pubmed: 25678394
J Clin Oncol. 2007 Mar 20;25(9):1099-106
pubmed: 17369573
Cardiovasc Intervent Radiol. 2013 Feb;36(1):158-65
pubmed: 22526099
J Clin Oncol. 2018 Apr 20;36(12):1232-1239
pubmed: 29528792
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):401-7
pubmed: 20950954
Am J Clin Oncol. 2017 Feb;40(1):27-34
pubmed: 25089529
Int J Cancer. 2003 May 20;105(1):117-22
pubmed: 12672041
Am J Clin Oncol. 2016 Apr;39(2):189-95
pubmed: 24441583
Ann Oncol. 2014 Mar;25(3):742-746
pubmed: 24510314
Melanoma Res. 2010 Jun;20(3):191-6
pubmed: 20335820
Cancer Rep (Hoboken). 2019 Aug;2(4):e1183
pubmed: 32721131
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Discov. 2013 Oct;3(10):1122-1129
pubmed: 23861464
Melanoma Res. 2016 Jun;26(3):300-3
pubmed: 26848796
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Cancer Invest. 2009 Jul;27(6):682-90
pubmed: 19219675
Curr Oncol Rep. 2017 Jul;19(7):45
pubmed: 28508938
Radiology. 2008 May;247(2):507-15
pubmed: 18349311
Ann Surg Oncol. 2010 Jul;17(7):1870-7
pubmed: 20221901
Melanoma Res. 2019 Dec;29(6):561-568
pubmed: 30664106
Immunotherapy. 2017 Dec;9(16):1323-1330
pubmed: 29185395